Purdue Insomnia Patents Wrongly Put To Bed, Fed. Circ. Told
Law360, Washington (January 4, 2016, 4:08 PM EST) -- Purdue Pharmaceutical urged a Federal Circuit panel Monday to reverse a New Jersey federal court's decision invalidating three sleep aid patents for being obvious in a dispute with Actavis Elizabeth, saying the patents used different dosages than other insomnia drugs did at the time.
The three patents behind the sleep aid Intermezzo took a novel approach by including a lower dosage of zolpidem, a hypnotic drug, to be taken during the middle of the night on an as-needed basis, Purdue Pharmaceutical Products LP told the three-judge panel. According to Purdue, other drugs on the market called for a high, prophylactic dosage...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.